Drug Approvals and Therapy Gains Drive 30 per cent Quarterly Revenue Jump

AstraZeneca Pharma India Limited reported a 30 per cent year-on-year increase in revenue from operations to Rs 682.80 crore for the quarter ended June 30, 2026, supported by growth across Oncology, Biopharmaceuticals and Rare Disease. The company attributed its Q1 FY2026-27 performance to disciplined execution in its core therapy areas, regulatory milestones and partnerships intended to expand access to innovative healthcare solutions in India. On the available reported basis, profit before exceptional item and Tax was Rs 51 crore. Profit after exceptional item and tax stood at Rs 50.70 crore. The company did not provide year-earlier profit figures in the reported information. Oncology generated revenue of Rs 464.90 crore during the quarter, an increase of 26 per cent from Q1 FY2025-26. Biopharmaceuticals, comprising CVRM, R&I and V&I, recorded revenue of Rs 161.90 crore, up 36 per cent year on year. Rare Disease revenue reached Rs 14.40 crore, representing a 35-fold increase from the corresponding quarter of the previous financial year. The pharmaceutical company also secured several regulatory approvals during the quarter. Acalabrutinib in combination with venetoclax, with or without obinutuzumab, was approved to treat patients with previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma. Acalabrutinib also received approval in combination with bendamustine and rituximab for adult patients with previously untreated mantle cell lymphoma who are not eligible for autologous stem cell transplant. Separately, trastuzumab deruxtecan in combination with pertuzumab was approved as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer classified as IHC3+ or ISH+. Beyond its medicines portfolio, AstraZeneca Pharma India signed a Memorandum of Understanding with the Government of Telangana to introduce AI-enabled lung cancer screening at public healthcare facilities. The collaboration involves deploying Qure.ai’s AI-powered chest X-ray solution to help clinicians identify high-risk pulmonary nodules and other lung conditions, supporting earlier triage and follow-up. The initiative is planned for 20 urban and rural public health facilities and includes training and upskilling healthcare professionals. The company also launched K+ Connect, a pan-India multidisciplinary initiative focused on improving hyperkalaemia management for patients with heart failure and chronic kidney disease. In addition, it introduced India Coronary Conquest 2026 with STEMI India. The clinician-led national complex PCI challenge is designed to support evidence-based learning and peer exchange among interventional cardiologists. Commenting on the performance, Bhavana Agrawal, Chief Financial Officer & Director of the Company, said, "We delivered 30% growth in the first quarter, bringing our revenue to INR 6,828 Mn. This performance builds on our strong track record of delivering a consistent double-digit growth over the last five years. Our focus remains on investing strategically in opportunities that support sustainable long-term value creation." Mr Praveen Rao Akkinepally, Country President & Managing Director, AstraZeneca Pharma India Ltd., added, "Our purpose is to push the boundaries of science to deliver life-changing medicines, and this shapes how we serve unmet patient needs in India. The growth and momentum in the first quarter reflects the strength of our portfolio and focus on expanding access to serve more patients in India." AstraZeneca Pharma India’s core therapy areas are Oncology, Biopharmaceuticals and Rare Disease. Its quarterly activities included medicines for blood cancers and HER2-positive breast cancer, public-sector lung screening, hyperkalaemia management and clinician education in complex PCI, combining pharmaceutical operations with healthcare access and professional learning initiatives in India.

Disclaimer: The article is for informational purposes only and not investment advice.